Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dare Bioscience, Inc. - Common Stock (NQ:DARE)

2.840 -0.250 (-8.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dare Bioscience, Inc. - Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
DARE Stock Earnings: Dare Bioscience Beats EPS, Beats Revenue for Q4 2023
DARE stock results show that Dare Bioscience beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Recap: Dare Bioscience Q4 Earnings
Via Benzinga
Dare Bioscience Earnings Preview
Via Benzinga
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of awareness. ARPA-H Sprint for Women's Health aims to promote innovative solutions. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to get into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning! 
Via InvestorPlace
Earnings Outlook For Dare Bioscience
Via Benzinga
Earnings Outlook For Dare Bioscience
Via Benzinga
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. 
Via Benzinga
Daré Bioscience Highlights Efficacy Data From Treatment Candidate For Painful Menstruation
Daré Bioscience Inc (NASDAQ: DARE) announced topline results from the Phase 1 DARE-PDM1-001 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1 an investigational... 
Via Benzinga
Recap: Dare Bioscience Q1 Earnings
Via Benzinga
Earnings Outlook For Dare Bioscience
Via Benzinga
Earnings Preview: Dare Bioscience
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Dare Bioscience: Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
FDA Gives Nod To Daré Bioscience's Trial Of Non-Hormonal Treatment For Dyspareunia, Seeks Additional Funding
Daré Bioscience Inc (NASDAQ: DARE) announced that the FDA has cleared its investigational new drug (IND) application for DARE-VVA1 as a non-hormonal treatment option for moderate to severe dyspareunia,... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 27 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 54 companies hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Daré Bioscience Shares Move Higher Intravaginal Ring Shows Promise In Menopause Symptoms
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
Women's Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow
Agile Therapeutics Inc. (NASDAQ: AGRX) is on a journey to fulfill the unmet health needs of women with products designed to provide them with contraceptive options. 
Via Benzinga
Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?
From Evofem Biosciences Inc.’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc.’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive,... 
Via TheNewswire.com
Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Can This Company's Birth Control Patch Disrupt The Contraceptive Market?
From Evofem Biosciences Inc.’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc.’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive,... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.